DM-5167 is under clinical development by Dime Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DM-5167’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DM-5167 overview
DM-5167 is under development for the treatment of solid tumors. The therapeutic candidate acts by targeting poly adenosine diphosphate ribose polymerase (PARP).
Dime Bio overview
Dime Bio, a biotechnology company which develops and manufactures microbiome-based therapeutics in the fields of synthetic biology, bioinformatics and drug development. The company is headquartered in Seongnam-si, Gyeonggi, South Korea.
For a complete picture of DM-5167’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.